Recent Publications

Smith MA, Morton CL,: Kolb, EA, Gorlick, R, Keir ST, Carol H, Lock RB, Kang MH, Reynolds CP, MD, Maris JM, Watkins AE, Houghton PJ: Initial testing (Stage 1) of mapatumumab (HGS-ETR1) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 54:307-10, 2010.
Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, Kang MH, Maris JM, Keir ST, Kolb EA, Wu J, Wozniak AW, Billups CA, Rubinstein L, Smith MA: Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Therapeutics 9:101-12, 2010.
Hazen RA, Eder M, Ph.D., Drotar D, Zyzanski S, Reynolds AE, M.F.A, Reynolds CP, Kodish E, Noll RB: A feasibility trial of a video intervention to improve informed consent for parents of children with leukemia Pediatr Blood Cancer 55:113-8, 2010.
Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick N, Raetz E, William Carroll W, Arceci A, Borowitz M, Gaynon P, Gore L, Jeha S, Maurer B, Siegel SE, Biondi A, Kearns P, Narendran A, Silverman L, Smith M, Zwaan M, Whitlock J: Toxicity assessment of new agents incorporated into induction regimens for pediatric acute lymphocytic leukemia (ALL): Results of an international consensus conference. Pediatr Blood Cancer 54:872-878, 2010.
Kang HG, Jenabi JM, Liu XF, Reynolds CP, Triche TJ, Sorensen PH: Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells. Mol Cancer Therapeutics 9:1396-407, 2010.
Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Wu J, Smith MA, Houghton PJ: Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer. 55:26-34, 2010.
Houghton PJ, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wu J, Smith MA: Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program. Pediatr Blood Cancer 54:921-6, 2010.
Lee J, Singh H, Maurer BJ, Reynolds CP, Kang MH: A validated LC with fluorescence detection method for simultaneous determination of safingol and D-erythro-sphinganine in human plasma. Chromatographia 71:1087-1091 2010.
Morton CL, Houghton PJ, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Wu J, Smith MA: Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer. 55:295-303, 2010.
Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA: Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program. Pediatr Blood Cancer. 55:668-77,2010.
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger RC, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM: Anti-GD2 antibody with GM-CSF, IL2 and isotretinoin for neuroblastoma: A Children's Oncology Group (COG) Phase III Study. New England J Medicine 363:22-32, 2010.
Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada S, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK: Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. New England J Medicine 363:1313-1323, 2010.
Houghton PJ, Morton CL, Kang MH, Reynolds CP, Billups CA, Favours E, Payne-Turner D, Tucker C, Smith MA: Evaluation of cytarabine against Ewing sarcoma xenografts by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 55:1224-6, 2010.
Shusterman SS, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MRA, Wagner B, Gan J, Eickhoff J, De Santes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, and Sondel PM: Anti-tumor activity of hu14.18-IL2 (EMD 273063) in relapsed/refractory neuroblastoma patients: a Children's Oncology Group (COG) phase II study. J Clinical Oncology 28:4969-75, 2010.
Cai, W, Maldonado V, Ji L, Sposto R, Reynolds CP, Keshelava N: Activity of irinotecan and temozolomide in the presence of O⁶-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models. Br J Cancer 103:1369-1379, 2010.
Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, Morton CL, Reynolds CP, Kang MH, Watkins A, Houghton PJ, Smith MA: Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer 55:1126-33,, 2010.
Hadjidaniel MD and Reynolds CP: Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by retinoic acid is mediated by the anti-apoptotic Bcl-2 family proteins. Mol Cancer Therapeutics 9:3164-74, 2010.
Kapranov P, St. Laurent G, Raz T, Fatih Ozsolak F, Reynolds CP, Sorensen PHB, Reaman G, Milos P, Arceci RJ, Thompson JF, Triche TJ: The majority of total nuclear-encoded non-ribosomal RNA in a human cell is "dark matter" unannotated RNA BMC Biology 8:149 [Epub] 2010
Carol H, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ, Lock RB: Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer 55:1329-37, 2010.
Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gu Y, Wilson WR, Smith MA: Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program Pediatr Blood Cancer. 2010 Dec 27. [Epub]
Kang MH, Smith MA, Morton CL, Nino Keshelava N, Houghton PJ, Reynolds CP: National Cancer Institute Pediatric Preclinical Testing Program: Model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 56:239-49, 2011.
Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Phelps D, Maris JM, Billups C, Smith MA: Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer (In Press, 2011).
Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ: Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010 Dec 22. [Epub]
Smith MA, Maris JM, Lock R, Kolb EA, Gorlick R, Keir ST, Carol H, Morton CL, Reynolds CP, Kang MH, Houghton PJ: Initial Testing (Stage 1) of the polyamine analog PG11047 by the Pediatric Preclinical Testing Program Pediatr Blood Cancer (In Press, 2011).
Reynolds CP, Kang MH, Keir ST, Gorlick R, Kolb EA, Lock R, Maris JM, Carol H, Morton CL, Billups CA, MS, Smith MA, MD, Houghton PJ: Initial testing of lenalidomide by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (In Press, 2011).
Cooper J, Kyunghwa H, Hardeep S, Wang, D, Reynolds CP, Robert C, Simon W, Maurer BJ, Kang MH: Fenretinide metabolism in humans and mice: Utilizing pharmacologic modulation of its metabolic pathway to increase systemic exposure. British J Pharmacology (In Press, 2011).
Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, Gorlick R, Kolb EA, Keir ST, Wu J, Wozniak AE, Yang Y, Manfredi M, Ecsedy J, Wang J, Neale G, Houghton PJ, Smith MA, Lock RB: Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol. 2011 Mar 30. [Epub ahead of print]
Kummar S, Gutierrez ME, Maurer BJ, Reynolds CP, Kang M, Singh H, Crandon S, Murgo AJ, Doroshow JH: Phase I trial of fenretinide Lym-X-sorb oral powder in adults with solid tumors and lymphomas. Anticancer Res. 31:961-6, 2011.
Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, Gorlick R, Kolb EA, Keir ST, Wu J, Wozniak AE, Yang Y, Manfredi M, Ecsedy J, Wang J, Neale G, Houghton PJ, Smith MA, Lock RB: Efficacy and pharmacokinetic/pharmcodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol. 2011 Mar 30. [Epub ahead of print]
Kang MH, Reynolds CP, Houghton PJ, Alexander D, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Wozniak A, Smith MA: Initial testing (stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011 Apr 29. doi: 10.1002/pbc.23154. [Epub ahead of print]
Houghton PJ, Lock R, Carol H, Morton CL, Gorlick R, Anders Kolb E, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups CA, Zhang MX, Madden SL, Teicher BA, Smith MA: Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011 May 5. doi: 10.1002/pbc.23016. [Epub ahead of print]
Lock RB, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gorlick R, Kolb EA, Houghton PJ, Smith MA. Initial testing of the CENP-E inhibitor SK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011 May 16. doi: 10.1002/pbc.23176. [Epub ahead of print]
Lock RB, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gorlick R, Kolb EA, Houghton PJ, Smith MA. Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011 May 16. doi: 10.1002/pbc.23176. [Epub ahead of print]
Villablanca JG, London WB, Naranjo A, McGrady MS, Ames MM, Joel M. Reid JM, McGovern RM, Buhrow SA, Stranzinger JH, Kitchen BJ, Sondel PM, Parisi M, Shulkin B, Yanik GA, Cohn S, Reynolds CP: Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: A report from the Children's Oncology Group NSC #374551; IND# 40294. Clinical Cancer Research 17:6858-6866, 2011.
Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Billups CA, Smith MA: Initial testing (Stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011 Jun 16. doi: 10.1002/pbc.23167. [Epub ahead of print]
Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT, Houghton PJ: Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer. doi: 10.1002/pbc.23319. [Epub ahead of print] 2011
Fang H, Harned TM, Kalous O, Maldonado V, DeClerck YA, Reynolds CP: Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma. Clinical Cancer Research 17:7093-104, 2011.
Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, Melendez EY, Smbatyan G, Moats RA, Rosol M, Biegel J, Reynolds CP: Novel cell lines accurately reflect pediatric brain tumors. J Neurooncology (In Press, 2011)
Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT, Kolb EA, Keir ST, Reynolds CP, Kang MH, Billups CA, Smith MA: Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011 Nov 18. doi: 10.1002/pbc.23412. [Epub ahead of print]
Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Billups CA, Smith MA: Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011 Nov 2. doi: 10.1002/pbc.23364. [Epub ahead of print]
Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, Kurmasheva RT, Reynolds CP, Kang MH, Wu J, Houghton PJ, Smith MA: Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer. 2011 Aug 16. doi: 10.1002/pbc.23290. [Epub ahead of print]
Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Morton CL, Wu J, Smith PG, Yu J, Houghton PJ: Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011 Oct 19. doi: 10.1002/pbc.23357. [Epub ahead of print]
MH Kang^†, N Harutyunyan, CP Hall, RA Papa, RB Lock. (2009). In vitro and in vivo Activity of Methotrexate and Aminopterin against acute lymphoblastic leukemia and lymphoma. Br. J. Haematol. 145, 389-393.
JP Cooper, S Bang, H Singh, SC Williams, MH Kang. (2011) Fenretinide cytotoxicity is independent of both constitutive and pharmacologically modulated glutathione levels in pediatric acute lymphoblastic leukemia cells cultured at hypoxia. Pediatric Blood Cancer. (in press).
C Zhang, YK Ryu, TZ Chen, CP Hall, DR Webster, MH Kang. (2011) Synergistic Activity of Rapamycin and Dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis. Leukemia Res. (in press).

Quick Search

SOM Cancer Center Resources

HSC Resources

Recent Publications